Checkpoint Therapeutics Future Growth
Future criteria checks 2/6
Checkpoint Therapeutics is forecast to grow earnings and revenue by 10.7% and 253.2% per annum respectively while EPS is expected to grow by 20.2% per annum.
Key information
10.7%
Earnings growth rate
20.2%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 253.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 41 | -40 | N/A | N/A | 2 |
| 12/31/2024 | 0 | -36 | N/A | N/A | 3 |
| 9/30/2024 | 0 | -46 | -31 | -31 | N/A |
| 6/30/2024 | 0 | -42 | -34 | -34 | N/A |
| 3/31/2024 | 0 | -52 | -40 | -40 | N/A |
| 12/31/2023 | 0 | -52 | -48 | -48 | N/A |
| 9/30/2023 | 0 | -54 | -56 | -56 | N/A |
| 6/30/2023 | 0 | -59 | -53 | -53 | N/A |
| 3/31/2023 | 0 | -56 | -52 | -52 | N/A |
| 12/31/2022 | 0 | -63 | -58 | -58 | N/A |
| 9/30/2022 | 0 | -71 | -52 | -52 | N/A |
| 6/30/2022 | 0 | -72 | -47 | -47 | N/A |
| 3/31/2022 | 0 | -67 | -41 | -41 | N/A |
| 12/31/2021 | 0 | -57 | -26 | -26 | N/A |
| 9/30/2021 | 0 | -37 | -22 | -22 | N/A |
| 6/30/2021 | 0 | -31 | -20 | -20 | N/A |
| 3/31/2021 | 0 | -26 | -17 | -17 | N/A |
| 12/31/2020 | 1 | -23 | -17 | -17 | N/A |
| 9/30/2020 | 1 | -22 | -16 | -16 | N/A |
| 6/30/2020 | 1 | -22 | -15 | -15 | N/A |
| 3/31/2020 | 2 | -22 | -18 | -18 | N/A |
| 12/31/2019 | 2 | -25 | -21 | -21 | N/A |
| 9/30/2019 | 5 | -28 | -24 | -24 | N/A |
| 6/30/2019 | 4 | -32 | -27 | -27 | N/A |
| 3/31/2019 | 4 | -33 | -29 | -29 | N/A |
| 12/31/2018 | 4 | -36 | -26 | -26 | N/A |
| 9/30/2018 | 1 | -31 | -22 | -22 | N/A |
| 6/30/2018 | 1 | -27 | N/A | -20 | N/A |
| 3/31/2018 | 1 | -27 | N/A | -18 | N/A |
| 12/31/2017 | 2 | -23 | N/A | -15 | N/A |
| 9/30/2017 | 2 | -25 | N/A | -15 | N/A |
| 6/30/2017 | 2 | -24 | N/A | -14 | N/A |
| 3/31/2017 | 3 | -23 | N/A | -11 | N/A |
| 12/31/2016 | 3 | -22 | N/A | -10 | N/A |
| 9/30/2016 | 2 | -22 | N/A | -7 | N/A |
| 6/30/2016 | 2 | -21 | N/A | -7 | N/A |
| 3/31/2016 | 0 | -16 | N/A | -5 | N/A |
| 12/31/2015 | 1 | -14 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CKPT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CKPT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CKPT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CKPT's revenue (253.2% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CKPT's revenue (253.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CKPT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:49 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Checkpoint Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Justin Walsh | B. Riley Securities, Inc. |
| Jonathan Aschoff | B. Riley Wealth |